Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.57 - $35.08 $5.19 Million - $19 Million
542,500 New
542,500 $16 Million
Q1 2022

May 17, 2022

SELL
$32.6 - $53.05 $4.16 Million - $6.77 Million
-127,700 Reduced 42.69%
171,400 $6.37 Million
Q4 2021

Feb 15, 2022

SELL
$36.77 - $90.91 $14.5 Million - $35.8 Million
-393,300 Reduced 56.8%
299,100 $13.1 Million
Q3 2021

Nov 16, 2021

BUY
$41.79 - $135.3 $18.1 Million - $58.7 Million
434,200 Added 168.16%
692,400 $43 Million
Q2 2021

Aug 16, 2021

BUY
$32.15 - $89.72 $2.04 Million - $5.69 Million
63,400 Added 32.55%
258,200 $22.1 Million
Q1 2021

May 18, 2021

BUY
$7.09 - $87.95 $527,496 - $6.54 Million
74,400 Added 61.79%
194,800 $8.76 Million
Q4 2020

Feb 17, 2021

SELL
$6.79 - $12.25 $46,851 - $84,525
-6,900 Reduced 5.42%
120,400 $821,000
Q3 2020

Nov 17, 2020

BUY
$2.86 - $11.51 $364,078 - $1.47 Million
127,300 New
127,300 $1.47 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.04B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.